Might Zoetis’ Impending Launch Explain Merck’s NYSE Chart Today?

With Pfizer’s Animal Health businesses set to debut (under the less-than awe-inspiring name “Zoetis”), as a partially independent public company on February 1, 2013, it struck me that the investment community may be awakening (see one small example) to the fact that ZoetisTM will be the largest animal health “pure play” on the planet. Zoetis will thus easily eclipse Merck’s similar businesses, in size and global reach.

In addition, and of concern to Whitehouse Station, Zoetis will no longer be competing for capital with the various higher-margin pure human pharma projects — at the allocation meetings, with ex-mother-Pfizer.

In fact, Zoetis will have its own public equity and debt markets to tap.

Finally, due to Zoetis’ shark repellant measures, Merck may well be dissuaded from trying any sort of re-roll up transaction, with the legacy Schering-Plough/Intervet animal health businesses.

Zoetis is poised to be the clear market leader here. Maybe that explains the rather disproportionate decline on the NYSE today, in Merck, compared to its peers.

We will keep an eye on this.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s